Welcome to our dedicated page for Zenas BioPharma news (Ticker: ZBIO), a resource for investors and traders seeking the latest updates and insights on Zenas BioPharma stock.
Zenas BioPharma, Inc. (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company focused on autoimmune diseases, and its news flow reflects active development across multiple programs. Company announcements frequently highlight progress with its lead product candidate, obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb across the B cell lineage to inhibit cells implicated in autoimmune disease without depleting them. News items include updates on the Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease (IgG4-RD), Phase 2 MoonStone trial in Relapsing Multiple Sclerosis (RMS), and Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE), including reports of statistically significant efficacy results and safety findings.
Investors following ZBIO news can also track developments related to orelabrutinib, a late-stage, highly selective CNS-penetrant, oral BTK inhibitor licensed from InnoCare Pharma. Press releases cover Phase 3 trials in Primary Progressive Multiple Sclerosis (PPMS) and planned trials in Secondary Progressive Multiple Sclerosis (SPMS), as well as partner-reported data in SLE. Additional news covers earlier-stage programs ZB021 and ZB022, described as potentially best-in-class oral IL-17AA/AF and TYK2 inhibitors in IND-enabling or preclinical stages.
Regulatory, financing and corporate updates are another key component of Zenas BioPharma’s news. The company issues releases on revenue participation and funding agreements, such as its obexelimab funding arrangement with Royalty Pharma, private placement financings, and material license agreements with InnoCare. Earnings-related press releases and Form 8-K–linked announcements provide context on cash runway, research and development spending, and strategic priorities.
This ZBIO news page aggregates these disclosures so readers can follow clinical milestones, regulatory plans, licensing transactions and capital raises associated with Zenas’ autoimmune pipeline. For investors, analysts and healthcare professionals, it offers a single view into how obexelimab, orelabrutinib, ZB021 and ZB022 are progressing through development and how the company is structuring partnerships and funding to support its programs.
Zenas BioPharma (Nasdaq: ZBIO) priced concurrent offerings totaling $300.0 million on March 27, 2026: $200.0 million principal of 2.50% convertible senior notes due 2032 and 5,000,000 common shares at $20.00 per share. Zenas expects aggregate net proceeds of approximately $287.5 million to fund the planned U.S. commercial launch of obexelimab if approved, advance orelabrutinib Phase 3 for progressive MS and ZB021 Phase 1/2 development, and for working capital and general corporate purposes. Closing is expected March 31, 2026, subject to customary conditions.
Zenas BioPharma (Nasdaq: ZBIO) commenced registered underwritten public offerings of convertible senior notes due April 1, 2032 and shares of common stock, each with a 30-day 15% over-allotment option. The offerings are separate and not conditioned on one another and are subject to market conditions.
The Company intends to use net proceeds to support a potential U.S. commercial launch of obexelimab for IgG4-RD if approved, advance orelabrutinib Phase 3 trials for progressive multiple sclerosis and ZB021 Phase 1 and 2 development, and for working capital and general corporate purposes.
Zenas BioPharma (Nasdaq: ZBIO) announced inducement equity grants on March 16, 2026 to newly hired employees: 235,700 stock options and 33,450 RSUs. Options carry a 10-year term and an exercise price of $23.23, equal to the closing price on the grant date.
Options vest over four years (25% at one year, then 36 monthly installments). RSUs vest in four equal annual installments on March 15, 2027–2030 and are subject to continued service and the 2026 Inducement Plan.
Zenas BioPharma (Nasdaq: ZBIO) reported Q4 and full-year 2025 results and a corporate update on March 16, 2026. Key items: obexelimab met INDIGO Phase 3 endpoints with a 56% reduction in IgG4-RD flare risk; BLA submission to FDA expected Q2 2026 and MAA to EMA H2 2026. Company closed a $250M senior secured debt facility with Pharmakon and held $360.5M cash at year-end. Revenue was $10.0M in 2025; net loss was $377.7M for the year.
Zenas BioPharma (Nasdaq: ZBIO) announced inducement grants dated February 17, 2026, awarding newly hired employees 35,700 stock options and 53,625 RSUs. The options carry a $26.77 exercise price, a ten-year term, and multi-year vesting under the company's 2026 Inducement Plan.
Options vest 25% after one year then monthly over three years; RSUs vest in four equal annual installments on Feb 15 each year from 2027–2030.
Zenas BioPharma (Nasdaq: ZBIO) reported Phase 2 MoonStone results for obexelimab in relapsing multiple sclerosis. Obexelimab achieved a 95% relative reduction in new gadolinium-enhancing T1 lesions over weeks 8 and 12 (p=0.0009) with near-complete suppression by week 8 and durable effect through week 24.
Adjusted mean lesions per scan were 0.01 vs 0.23 for placebo; serum NfL declined 40% by week 24. Safety was consistent with prior trials and no new safety signals were observed.
Zenas BioPharma (NASDAQ: ZBIO) said management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 1:30 p.m. ET. A live webcast and archived replay will be available under Events and Presentations in the Investor & Media Relations section of the company website.
Zenas BioPharma (Nasdaq: ZBIO) announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) dated Jan 15, 2026. The Compensation Committee granted a non-qualified stock option to a newly hired employee to purchase 100,000 shares of common stock.
The option has a 10-year term, an exercise price of $19.93 per share (equal to the closing price on the grant date), and vests over 4 years (25% after one year, then 36 equal monthly installments), subject to continued service and the terms of the 2026 Inducement Plan and the related option agreement.
Zenas BioPharma (Nasdaq: ZBIO) announced positive Phase 3 INDIGO results for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD). Obexelimab met the primary endpoint with a 56% reduction in risk of IgG4-RD flare versus placebo (Hazard Ratio 0.44, p=0.0005) over 52 weeks and achieved statistically significant results on all four key secondary endpoints. The drug was well tolerated with no new safety signals, similar injection site reaction rates, and lower infection rates versus placebo. Zenas plans to submit a BLA to FDA in Q2 2026 and an MAA to EMA in H2 2026. Full INDIGO data will be presented at a future medical meeting and a conference call was scheduled for January 5, 2026.
Zenas BioPharma (Nasdaq: ZBIO) announced inducement option grants on December 15, 2025 to two newly hired employees totaling 300,000 non-qualified stock options. The options have a 10-year term and an exercise price of $32.59, equal to the closing price on the grant date. Vesting is over four years: 25% on the one-year anniversary of each employee's start date, then the remainder in 36 equal monthly installments, subject to continued service. Grants are governed by an Inducement Option Award Agreement and were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).